Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA; Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
J Hepatol. 2024 Jul;81(1):120-134. doi: 10.1016/j.jhep.2024.02.018. Epub 2024 Feb 28.
BACKGROUND & AIMS: The PTEN-AKT pathway is frequently altered in extrahepatic cholangiocarcinoma (eCCA). We aimed to evaluate the role of PTEN in the pathogenesis of eCCA and identify novel therapeutic targets for this disease.
The Pten gene was genetically deleted using the Cre-loxp system in biliary epithelial cells. The pathologies were evaluated both macroscopically and histologically. The characteristics were further analyzed by immunohistochemistry, reverse-transcription PCR, cell culture, and RNA sequencing. Some features were compared to those in human eCCA samples. Further mechanistic studies utilized the conditional knockout of Trp53 and Aurora kinase A (Aurka) genes. We also tested the effectiveness of an Aurka inhibitor.
We observed that genetic deletion of the Pten gene in the extrahepatic biliary epithelium and peri-ductal glands initiated sclerosing cholangitis-like lesions in mice, resulting in enlarged and distorted extrahepatic bile ducts in mice as early as 1 month after birth. Histologically, these lesions exhibited increased epithelial proliferation, inflammatory cell infiltration, and fibrosis. With aging, the lesions progressed from low-grade dysplasia to invasive carcinoma. Trp53 inactivation further accelerated disease progression, potentially by downregulating senescence. Further mechanistic studies showed that both human and mouse eCCA showed high expression of AURKA. Notably, the genetic deletion of Aurka completely eliminated Pten deficiency-induced extrahepatic bile duct lesions. Furthermore, pharmacological inhibition of Aurka alleviated disease progression.
Pten deficiency in extrahepatic cholangiocytes and peribiliary glands led to a cholangitis-to-cholangiocarcinoma continuum that was dependent on Aurka. These findings offer new insights into preventive and therapeutic interventions for extrahepatic CCA.
The aberrant PTEN-PI3K-AKT signaling pathway is commonly observed in human extrahepatic cholangiocarcinoma (eCCA), a disease with a poor prognosis. In our study, we developed a mouse model mimicking cholangitis to eCCA progression by conditionally deleting the Pten gene via Pdx1-Cre in epithelial cells and peribiliary glands of the extrahepatic biliary duct. The conditional Pten deletion in these cells led to cholangitis, which gradually advanced to dysplasia, ultimately resulting in eCCA. The loss of Pten heightened Akt signaling, cell proliferation, inflammation, fibrosis, DNA damage, epigenetic signaling, epithelial-mesenchymal transition, cell dysplasia, and cellular senescence. Genetic deletion or pharmacological inhibition of Aurka successfully halted disease progression. This model will be valuable for testing novel therapies and unraveling the mechanisms of eCCA tumorigenesis.
PTEN-AKT 通路在外周型胆管癌(eCCA)中经常发生改变。我们旨在评估 PTEN 在 eCCA 发病机制中的作用,并为该疾病确定新的治疗靶点。
使用 Cre-loxp 系统在胆管上皮细胞中遗传缺失 Pten 基因。通过大体和组织学评估病理学。通过免疫组织化学、逆转录 PCR、细胞培养和 RNA 测序进一步分析特征。将一些特征与人类 eCCA 样本进行比较。进一步的机制研究利用 Trp53 和 Aurora 激酶 A(Aurka)基因的条件敲除。我们还测试了 Aurka 抑制剂的有效性。
我们观察到,在肝外胆管上皮细胞和周围腺上皮细胞中遗传缺失 Pten 基因,在出生后 1 个月内,可导致小鼠发生类似于硬化性胆管炎的病变,导致肝外胆管扩大和变形。组织学上,这些病变表现为上皮细胞增殖增加、炎症细胞浸润和纤维化。随着年龄的增长,病变从低级别发育不良进展为浸润性癌。Trp53 失活进一步加速了疾病的进展,可能通过下调衰老。进一步的机制研究表明,人类和小鼠的 eCCA 均表现出 AURKA 的高表达。值得注意的是,Aurka 的遗传缺失完全消除了 Pten 缺乏诱导的肝外胆管病变。此外,Aurka 的药理抑制可缓解疾病进展。
肝外胆管细胞和周围腺上皮细胞中的 Pten 缺失导致依赖于 Aurka 的胆管炎到胆管癌的连续过程。这些发现为预防和治疗肝外 CCA 提供了新的见解。
PTEN-PI3K-AKT 信号通路的异常在人类外周型胆管癌(eCCA)中很常见,这是一种预后不良的疾病。在我们的研究中,我们通过 Pdx1-Cre 在肝外胆管的上皮细胞和周围腺上皮细胞中条件性地缺失 Pten 基因,建立了一种模拟胆管炎到 eCCA 进展的小鼠模型。这些细胞中 Pten 的条件性缺失导致胆管炎,逐渐进展为发育不良,最终导致 eCCA。Pten 的缺失增强了 Akt 信号、细胞增殖、炎症、纤维化、DNA 损伤、表观遗传信号、上皮-间充质转化、细胞发育不良和细胞衰老。Aurka 的基因缺失或药理抑制成功阻止了疾病的进展。该模型将有助于测试新的治疗方法并揭示 eCCA 肿瘤发生的机制。